The NuroSleeve, a user-centered 3D printed hybrid orthosis for individuals with upper extremity impairment.
Mehdi Khantan, Mikael Avery, Phyo Thuta Aung and 5 others
PMID 37542335WHAT IT FOUND
Five stroke survivors used a custom 3D-printed sleeve with electrical stimulation for eight weeks.
Most reported clinically meaningful improvements in daily tasks when wearing the device. This is a small feasibility study, not proof of efficacy.
Key findings
01Four of the five participants reported clinically meaningful improvements (a score increase of at least 2 points) in performance or satisfaction on their self-selected daily goals when using the device.
02The device was worn comfortably, with the splint itself weighing between 175 and 310 grams, and participants were able to don and doff it independently.
03The joystick was the preferred and most reliable control method for all five participants, while EMG control was found to be erratic and was not widely adopted.
STILL TO COME
How it was doneWhat they foundWhat it means for OTs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The clinical evaluation involved only five participants, making it a small feasibility study rather than a powered trial. There was no control group; participants served as their own controls, and improvements cannot be separated from the natural course of rehabilitation or the placebo effect of using a new device. Voice control and EMG control were either unavailable or unreliable for the participants included in this report. The study did not report secondary outcomes like standardized motor tests (ARAT, BBT) in this paper, limiting the comparison of functional motor recovery. Bench testing showed the linear actuator failed under high-duty-cycle stress, raising questions about long-term durability in real-world use, though real-world battery life was better than expected.
Declared interests
The research was supported by non-U.S. government funds. The device is under development for commercialization, and the authors describe a plan for FDA clearance and future pivotal trials.
The easy way to misread this
Do not interpret the improvements as proof that the NuroSleeve causes superior functional recovery compared to standard care. This was a small, uncontrolled feasibility study with five participants, and the authors explicitly state that a randomized controlled trial is needed to determine efficacy.